Valuation is based on a normalized EV/EBITDA multiple of ~7x (in line with HME and healthcare services peers) applied to the midpoint of 2026 EBITDA guidance ($505M), subtracting net debt (~$1B post-divestiture), and using the most recent reported share count (147M). Growth is strong and recurring,…
AdaptHealth (AHCO) Q2 2026: Portfolio Pruning Drives 16% Organic Growth, Margin Reset on $40M West Coast Drag
AdaptHealth delivered double-digit organic growth, but near-term profitability was pressured by operational and supplier headwinds. The company executed a sweeping portfolio refocus, divesting diabetes health, exiting low-margin wellness products, and forming a JV for e-commerce, all to sharpen its core. Margin recovery and cost discipline are now central, with management signaling that recent growing pains will position AHCO for long-term efficiency and resilience.
Summary
- Strategic Refocus Drives Core Strength: Diabetes divestiture and wellness exits concentrate resources on sleep and respiratory.
- Operational Strain from Capitated Scale-Up: West Coast contract overruns and supplier pricing reset near-term margin trajectory.
- Margin Recovery in Focus: Technology, cost cuts, and contract optimization underpin path to normalized profitability.
Business Overview
AdaptHealth is a leading provider of home medical equipment (HME), specializing in sleep therapy, respiratory care, and supporting products delivered to patients’ homes. The company generates revenue through a mix of fee-for-service and capitated contracts, serving health systems, payers, and direct-to-consumer channels. Its major segments include Sleep Health, Respiratory Health, and Wellness at Home, with recent divestitures narrowing the focus to core, higher-margin categories.
Performance Analysis
Second quarter results showed robust organic growth, with revenue from continuing operations up nearly 16% and record volume gains across all core segments. The West Coast capitated contract, now accounting for 14% of revenue, provided a major growth engine but also surfaced significant operational challenges, including higher-than-expected order volumes and workflow inefficiencies. These issues, coupled with a sudden price hike from a large manufacturer, weighed on adjusted EBITDA and compressed margins below historical norms.
Segment performance was mixed: Sleep Health and Respiratory Health both delivered double-digit growth, while Wellness at Home lagged with mid-single-digit gains and is now being pruned of non-strategic products. Free cash flow was negative due to heavy capital investment supporting the new contract ramp, but management expects normalization as capex moderates and portfolio actions take hold.
- Capitated Revenue Expansion: Capitated contracts, especially on the West Coast and with Humana, drove more than threefold YoY growth in this model, now representing a material revenue mix shift.
- Margin Compression from Operational Overruns: The West Coast contract missed internal profit targets by $15 million in Q2, with a further $40 million impact expected in the second half due to cost overruns and inefficiencies.
- Supplier Price Shock: An abrupt contract termination and price increase from a key manufacturer created a $30 million headwind for the back half of the year, with mitigation efforts underway but outcomes uncertain.
While top-line growth remains a bright spot, the quarter was defined by a reset in profitability expectations and a sharpened focus on core business execution.
Executive Commentary
"We signed a definitive agreement to sell our diabetes health business for $235 million, a move that we expect will ultimately improve our growth rate, enhance our margin profile, and allow us to sidestep looming industry risk."
Suzanne Foster, Chief Executive Officer
"The West Coast Capitated Contract missed our expectations by $15 million, so we are adjusting for this run rate in full-year guidance that I will cover later."
Jason Clemens, Chief Financial Officer
Strategic Positioning
1. Portfolio Simplification and Core Focus
AHCO executed a disciplined portfolio pruning, divesting its diabetes health business, discontinuing low-margin wellness products, and spinning off its e-commerce CPAP Shop into a joint venture. This refocus enables capital and management attention to be redeployed into sleep and respiratory, where AHCO holds scale and competitive advantage. The company expects improved growth rates, higher margins, and reduced exposure to reimbursement risk as a result.
2. Capitated Model Scale and Learning Curve
Capitated contracts, where AHCO receives a fixed payment per patient, have become a major strategic lever, especially with the West Coast and Humana expansions. While these deals provide revenue visibility and a path to exclusive provider status, the West Coast rollout exposed cost and workflow risks, highlighting the need for operational discipline and technology-driven efficiency. Management maintains that capitation, when balanced with fee-for-service, will be a durable pillar of future growth.
3. Technology-Enabled Patient Experience and Cost Control
Digital transformation is a central theme, with the MyApp platform now integrating nearly the entire patient journey—from intake to AI-powered mask fitting and supply ordering. This not only enhances patient engagement but also reduces manual labor, accelerates cost takeout, and positions AHCO for scalable growth. Early results show rapid adoption and improved order conversion, supporting both margin recovery and top-line growth.
4. Cost Restructuring and Overhead Rationalization
A $19 million annualized workforce reduction and targeted cost actions are underway to realign the expense base with the streamlined business. Management expects to remove half of the stranded overhead from the diabetes divestiture within 12 months, with additional efficiency gains as organic growth and disciplined M&A bring more revenue onto a leaner platform.
Key Considerations
This quarter marked a decisive transition, as AdaptHealth moved from a broad, acquisition-driven portfolio to a focused, technology-enabled core business. The company faces near-term margin and cash flow headwinds but is positioning for improved long-term returns.
Key Considerations:
- Portfolio Reset as Margin Catalyst: The diabetes divestiture and wellness exits remove low-growth, low-margin drag and free up resources for higher-return segments.
- Capitated Model Execution Risk: Scaling capitated contracts brings operational complexity and cost risk, as shown by the $40 million West Coast profit drag, but offers long-term exclusivity and administrative savings.
- Supplier Leverage and Pricing Power: The abrupt price hike from a major manufacturer highlights vulnerability to supplier concentration and contractual uncertainty.
- Technology as a Margin Lever: MyApp adoption and workflow automation are critical to offsetting labor and logistics inflation, with early signs of success in patient conversion and cost reduction.
- Balance Sheet and Capital Allocation Discipline: Debt paydown remains a priority, with proceeds from divestitures earmarked for leverage reduction and selective tuck-in M&A to rebuild scale in core areas.
Risks
Key risks include continued operational overruns in capitated contracts, inability to renegotiate or pass through supplier price increases, and delayed realization of cost savings from recent restructuring. Regulatory constraints, such as the DME moratorium, limit the ability to leverage new infrastructure for incremental revenue. Supplier concentration and abrupt contract changes could further pressure margins. Execution on technology and cost initiatives is critical to restoring profitability.
Forward Outlook
For Q3 2026, AdaptHealth guided to:
- Net revenue of $720 to $740 million
- Adjusted EBITDA margin of approximately 17.9%
- Free cash flow of approximately $50 million
For full-year 2026, management reset guidance to:
- Net revenue of $2.85 to $2.89 billion (excluding diabetes health)
- Adjusted EBITDA of $490 to $520 million
Management highlighted several factors that will shape results:
- Sequential margin improvement expected as West Coast contract stabilizes and cost actions ramp
- Active negotiations with suppliers and ongoing portfolio optimization to mitigate headwinds
Takeaways
AdaptHealth’s Q2 was a turning point, with decisive portfolio actions and operational resets positioning the company for a more focused, efficient future.
- Portfolio Discipline: The diabetes divestiture and wellness pruning mark the end of a multi-year portfolio simplification, concentrating resources on segments with the clearest path to scale and profitability.
- Margin Recovery Path: Margin headwinds from the West Coast contract and supplier price increases are being addressed through cost cuts, technology, and contract renegotiation, but require flawless execution in coming quarters.
- Technology and Core Growth: Digital transformation and a refocused sales and service strategy underpin management’s confidence in future margin expansion and growth acceleration as operational kinks are resolved.
Conclusion
AdaptHealth’s Q2 2026 marked a strategic inflection, as management completed its portfolio overhaul and pivoted to margin recovery amid operational and supplier shocks. Near-term results are pressured, but the company’s sharpened focus and technology investments provide a credible path to improved efficiency and long-term value creation.
Industry Read-Through
AdaptHealth’s quarter highlights the challenges of scaling capitated models in home medical equipment, especially when rapid patient transitions and workflow complexity collide. The abrupt supplier price increase is a warning for others in the sector about the risks of vendor concentration and the need for robust contract management. The move toward portfolio simplification and digital patient engagement is likely to be echoed across the industry, as providers seek to boost margins and defend against reimbursement and regulatory pressures. For health systems and payers, AHCO’s experience underscores the operational demands and partnership depth required to make capitation work at scale.